600518 Stock Overview
Produces and sells Chinese herbal medicines in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Kangmei Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥2.22 |
| 52 Week High | CN¥2.95 |
| 52 Week Low | CN¥1.68 |
| Beta | 0.56 |
| 1 Month Change | -0.89% |
| 3 Month Change | 4.23% |
| 1 Year Change | 23.33% |
| 3 Year Change | -31.06% |
| 5 Year Change | -34.32% |
| Change since IPO | 64.58% |
Recent News & Updates
We Think Kangmei Pharmaceutical (SHSE:600518) Can Stay On Top Of Its Debt
Jan 27
Subdued Growth No Barrier To Kangmei Pharmaceutical Co., Ltd. (SHSE:600518) With Shares Advancing 35%
Nov 08We Think Kangmei Pharmaceutical's (SHSE:600518) Robust Earnings Are Conservative
Nov 06Recent updates
We Think Kangmei Pharmaceutical (SHSE:600518) Can Stay On Top Of Its Debt
Jan 27Subdued Growth No Barrier To Kangmei Pharmaceutical Co., Ltd. (SHSE:600518) With Shares Advancing 35%
Nov 08We Think Kangmei Pharmaceutical's (SHSE:600518) Robust Earnings Are Conservative
Nov 06Is Kangmei Pharmaceutical (SHSE:600518) A Risky Investment?
Oct 28What Kangmei Pharmaceutical Co., Ltd.'s (SHSE:600518) P/S Is Not Telling You
Aug 03We Think Kangmei Pharmaceutical (SHSE:600518) Can Stay On Top Of Its Debt
Jun 17Kangmei Pharmaceutical's (SHSE:600518) Performance Is Even Better Than Its Earnings Suggest
May 06Kangmei Pharmaceutical Co., Ltd.'s (SHSE:600518) Price Is Out Of Tune With Revenues
Apr 10Shareholder Returns
| 600518 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 0% | 0% | 0% |
| 1Y | 23.3% | 15.4% | 25.6% |
Return vs Industry: 600518 exceeded the CN Pharmaceuticals industry which returned 15.4% over the past year.
Return vs Market: 600518 underperformed the CN Market which returned 25.6% over the past year.
Price Volatility
| 600518 volatility | |
|---|---|
| 600518 Average Weekly Movement | 8.0% |
| Pharmaceuticals Industry Average Movement | 5.3% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in CN Market | 10.7% |
| 10% least volatile stocks in CN Market | 3.9% |
Stable Share Price: 600518 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 600518's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 4,409 | Guowei Liu | www.kangmei.com.cn |
Kangmei Pharmaceutical Co., Ltd. produces and sells Chinese herbal medicines in China. It also offers Chinese patent medicines, chemical medicines, food, and health food; operation of Chinese medicinal materials markets; produces and sells medical devices; and pharmaceutical logistics system. The company provides its products through medical institution resources, smart pharmacies, OTC retail, chain drug stores, direct sales, medical e-commerce, mobile medical care, etc. Kangmei Pharmaceutical Co., Ltd.
Kangmei Pharmaceutical Co., Ltd. Fundamentals Summary
| 600518 fundamental statistics | |
|---|---|
| Market cap | CN¥30.78b |
| Earnings (TTM) | CN¥255.55m |
| Revenue (TTM) | CN¥5.21b |
120.4x
P/E Ratio5.9x
P/S RatioIs 600518 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 600518 income statement (TTM) | |
|---|---|
| Revenue | CN¥5.21b |
| Cost of Revenue | CN¥4.55b |
| Gross Profit | CN¥665.09m |
| Other Expenses | CN¥409.54m |
| Earnings | CN¥255.55m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Apr 19, 2025
| Earnings per share (EPS) | 0.018 |
| Gross Margin | 12.76% |
| Net Profit Margin | 4.90% |
| Debt/Equity Ratio | 0.2% |
How did 600518 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/04 15:55 |
| End of Day Share Price | 2025/01/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Kangmei Pharmaceutical Co., Ltd. is covered by 17 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Shuchang Liu | Changjiang Securities Co. LTD. |
| Pei Hui Tang | Chasing Securities |
| Peng Zou | China International Capital Corporation Limited |